Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MME | P08473 | 3/20 | 0.46 |
| ▸ | ECE1 | P42892 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 3/20 | 0.43 |
| ▸ | MMP9 | P14780 | 2/20 | 0.43 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8697150 | 0.87 | MME (0.47) | L3MBTL1MMEECE1MEN1KMT2A | |
| SCHEMBL31510352 | 0.84 | ANPEP (0.48) | L3MBTL1MMEECE1MEN1KMT2A | |
| SCHEMBL3103119 | 0.83 | FPR2 (0.54) | L3MBTL1MMEECE1MEN1KMT2A | |
| SCHEMBL43350 | 0.81 | MME (0.62) | L3MBTL1MMEECE1MEN1KMT2A | |
| SCHEMBL43351 | 0.81 | MME (0.62) | L3MBTL1MMEECE1MEN1KMT2A | |
| SCHEMBL16415834 | 0.81 | MME (0.49) | L3MBTL1MMEECE1MEN1KMT2A | |
| SCHEMBL7348038 | 0.79 | MME (0.51) | MMEACE | |
| SCHEMBL7322712 | 0.79 | MME (0.51) | MMEACE | |
| SCHEMBL7407175 | 0.78 | MME (0.48) | MMEACE | |
| Ammonia Solution, Strong SCHEMBL2415758 | 0.77 | MME (0.49) | L3MBTL1MMEECE1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148715-A1 | Structural requirements for STAT3 binding and recruitment to phosphotyrosine ligands | BAYLOR COLLEGE OF MEDICINE (US) | 2006-07-06 | — | — | US | claimed |
| WO-2006069001-A2 | STRUCTURAL REQUIREMENTS FOR STAT3 BINDING AND RECRUITMENT TO PHOSPHOTOTYROSINE LIGANDS | BAYLOR COLLEGE OF MEDICINE (US) | 2006-06-29 | — | — | WO | claimed |
| US-5801149-A | PEPTIDS FOR INHIBITION OF PROTEINS | JOSLIN D-ABETES CENTER, INC. (US) | 1998-09-01 | — | — | US | claimed |
| WO-1994008600-A1 | INHIBITION OF SIGNAL TRANSDUCTION MOLECULES | JOSLIN DIABETES CENTER (US) | 1994-04-28 | — | — | WO | claimed |
| CN-119136833-A | Membrane translocation domain and uses thereof | 俄亥俄州创新基金会 | 2024-12-13 | — | — | CN | disclosed |
| CN-115135665-A | Cyclic proteins comprising cell penetrating peptides | 俄亥俄州国家创新基金会 | 2022-09-30 | — | — | CN | disclosed |
| CN-113861268-A | Cell penetrating peptides and methods of making and using the same | 恩特拉达治疗学股份有限公司 | 2021-12-31 | — | — | CN | disclosed |
| CN-106852146-B | Cell penetrating peptides and methods of making and using the same | 恩特拉达治疗学股份有限公司 | 2021-08-13 | — | — | CN | disclosed |
| US-20210196842-A1 | SITE-SPECIFIC RADIOFLUORINATION OF PEPTIDES WITH 8-[18F]-FLUOROOCTANOIC ACID CATALYZED BY LIPOIC ACID LIGASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-07-01 | — | — | US | disclosed |
| CN-111447941-A | Polypeptide conjugates for intracellular delivery of binding peptides | 俄亥俄州国家创新基金会 | 2020-07-24 | — | — | CN | disclosed |
| WO-2017095806-A1 | SITE-SPECIFIC RADIOFLUORINATION OF PEPTIDES WITH 8-[18F]-FLUOROOCTANOIC ACID CATALYZED BY LIPOIC ACID LIGASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-06-08 | — | — | WO | disclosed |
| EP-2267029-B1 | Methods and compositions for treatment of inflammatory disease using Cadherin-11 modulating agents | BRIGHAM & WOMENS HOSPITAL (US) | 2016-06-15 | — | — | EP | disclosed |
| WO-2001017557-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF INFLAMMATORY DISEASE USING CADHERIN-11 MODULATING AGENTS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2001-03-15 | — | — | WO | disclosed |
| EP-0768821-A4 | pp60PIK : A DOWNSTREAM ELEMENT IN INSULIN SIGNALING | JOSLIN DIABETES CENTER INC (US) | 1999-10-27 | — | — | EP | disclosed |
| US-5801149-A | PEPTIDS FOR INHIBITION OF PROTEINS | JOSLIN D-ABETES CENTER, INC. (US) | 1998-09-01 | — | — | US | disclosed |
| US-5650293-A | PROTEIN THAT MEDIATES INSULIN REGULATION OF 3'-PHOSPHATIDYL INOSITOL KINASE WITH NUCLEIC ACID SEQUENCES | JOSLIN DIABETES CENTER, INC. (US) | 1997-07-22 | — | — | US | disclosed |
| WO-1997008300-A9 | CRYSTALLINE ZAP FAMILY PROTEINS | — | 1997-05-22 | — | — | WO | disclosed |
| EP-0768821-A1 | pp60PIK : A DOWNSTREAM ELEMENT IN INSULIN SIGNALING | THE JOSLIN DIABETES CENTER, INC. (US) | 1997-04-23 | — | — | EP | disclosed |
| WO-1995034201-A1 | pp60PIK: A DOWNSTREAM ELEMENT IN INSULIN SIGNALING | JOSLIN DIABETES CENTER, INC. (US) | 1995-12-21 | — | — | WO | disclosed |
| WO-1994008600-A1 | INHIBITION OF SIGNAL TRANSDUCTION MOLECULES | JOSLIN DIABETES CENTER (US) | 1994-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210196842-A1 | SITE-SPECIFIC RADIOFLUORINATION OF PEPTIDES WITH 8-[18F]-FLUOROOCTANOIC ACID CATALYZED BY LIPOIC ACID LIGASE | DLAT, FABP7, ACSL1 | L3MBTL1 317/4885MME 167/4885ECE1 548/4885 |
| US-20060148715-A1 | Structural requirements for STAT3 binding and recruitment to phosphotyrosine ligands | STAT3, JAK2, STAT5B | L3MBTL1 597/4885MME 2404/4885ECE1 3306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.